Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-23 production. [GOC:mah]
Negative regulation of interleukin-23 (IL-23) production is a crucial process that helps maintain immune homeostasis and prevent excessive inflammation. IL-23 is a pro-inflammatory cytokine primarily produced by dendritic cells and macrophages in response to microbial stimuli. Its dysregulation can contribute to various inflammatory and autoimmune disorders, such as psoriasis, inflammatory bowel disease, and multiple sclerosis.
The negative regulation of IL-23 production involves a complex interplay of cellular and molecular mechanisms, including:
**1. Transcriptional Regulation:**
* **Suppressor of Cytokine Signaling (SOCS) proteins:** SOCS1 and SOCS3 are key inhibitors of IL-23 production. They bind to the IL-23 receptor complex, blocking downstream signaling pathways.
* **MicroRNAs (miRNAs):** Specific miRNAs, such as miR-146a and miR-155, have been shown to suppress IL-23 production by targeting its mRNA or the mRNA of its signaling components.
* **Transcription factors:** Transcription factors like STAT3 and NF-κB play a crucial role in IL-23 gene expression. Their activity can be negatively regulated by various mechanisms, including phosphorylation, ubiquitination, and interaction with inhibitory proteins.
**2. Post-translational Modification:**
* **Ubiquitination:** IL-23 can be targeted for degradation through ubiquitination, a process that marks proteins for proteasomal degradation.
* **Glycosylation:** Glycosylation of IL-23 can influence its stability and activity, potentially leading to reduced production.
**3. Cellular Mechanisms:**
* **Immunoregulatory cells:** Regulatory T cells (Tregs) and other immune cells can suppress IL-23 production by various mechanisms, including the release of anti-inflammatory cytokines, such as IL-10 and TGF-β.
* **Apoptosis:** Apoptosis, or programmed cell death, can eliminate cells producing IL-23, thereby reducing its production.
* **Exosomes:** Exosomes, small vesicles released by cells, can carry molecules that inhibit IL-23 production in recipient cells.
**4. Environmental Factors:**
* **Dietary components:** Certain dietary components, such as omega-3 fatty acids and probiotics, have been shown to modulate IL-23 production.
* **Lifestyle factors:** Factors like physical activity and stress levels can influence the immune response and IL-23 production.
**5. Therapeutic Interventions:**
* **Anti-IL-23 therapies:** Monoclonal antibodies targeting IL-23, such as ustekinumab and risankizumab, have been developed for the treatment of inflammatory disorders.
* **Immunomodulators:** Drugs that modulate the immune system, such as anti-TNF-α therapies, can indirectly affect IL-23 production.
In conclusion, negative regulation of IL-23 production is a multi-faceted process involving diverse cellular and molecular mechanisms. It is essential for maintaining immune homeostasis and preventing uncontrolled inflammation. Dysregulation of this process can contribute to the development of various inflammatory and autoimmune diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Ras-related C3 botulinum toxin substrate 1 | A Ras-related C3 botulinum toxin substrate 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P63000] | Homo sapiens (human) |
Toll-like receptor 4 | A Toll-like receptor 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:O00206] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
carvedilol | carbazoles; secondary alcohol; secondary amino compound | alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent | |
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
ketorolac | 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively. ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure. Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed) | amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate | analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug |
sanguinarine chloride | |||
chelerythrine chloride | |||
methotrexate | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent | |
perifosine | ammonium betaine; phospholipid | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | |
ruboxistaurin | ruboxistaurin: inhibits protein kinase C beta; structure in first source | ||
s 1033 | (trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide | anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor | |
parthenolide | sesquiterpene lactone | drug allergen; inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug | |
sotrastaurin | sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients. sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source | indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines | anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent |
resatorvid | |||
gdc-0973 | cobimetinib : A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. cobimetinib: has antineoplastic activity; structure in first source | aromatic amine; difluorobenzene; N-acylazetidine; organoiodine compound; piperidines; secondary amino compound; tertiary alcohol | antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |
azd5438 | sulfonamide | ||
nsc 23766 | NSC 23766 trihydrochloride : A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1). Rac1 inhibitor : Any inhibitor of Rac1. | hydrochloride | antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist |
crx-526 | CRX-526: aminoalkyl-glucosaminide-phosphate; lipid A-mimetic with anti-inflammatory properties; structure in first source | ||
at13148 | |||
poziotinib | HM781-36B: antitumor irreversible Pan-HER inhibitor for treatment of gastric cancer | acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline | antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist |
bay 869766 | |||
gilteritinib | gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor | aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound | antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
glpg0634 |